TNF-α Inhibitors Linked to Lower Glaucoma Risk

A new study reveals that certain arthritis medications may reduce the likelihood of developing primary open-angle glaucoma.

Updated on Oct. 27, 2026 in Arthritis

Isometric editorial illustration of a crystalline retinal lattice structure being viewed through a circular magnifying lens. — A retrospective study of over 23,000 patients indicates that TNF-α inhibitors may significantly lower the risk of developing open-angle glaucoma. AI Illustration. Upload story photo >

Live Poll

Does new research on existing drugs change your trust in your current medical treatment plan?

A large-scale retrospective study found that patients using TNF-α inhibitors had a 30% lower relative risk of being diagnosed with primary open-angle glaucoma. The findings suggest that these therapies may offer protective effects against glaucomatous neurodegeneration.

Why it matters

Understanding the link between tumor necrosis factor-alpha and glaucoma could offer new avenues for managing eye health in patients with chronic inflammatory conditions. This discovery helps researchers clarify the role of systemic inflammation in the development of vision-threatening eye diseases.

The study analyzed 11,915 matched pairs of patients, showing a 30% relative risk reduction for POAG diagnosis and lower rates of required ocular interventions. Participants were adults aged 40 and older, with 48% of the treatment group being managed for rheumatoid arthritis.

The players

American Journal of Ophthalmology

This is a peer-reviewed medical journal that publishes research on the practice and science of ophthalmology.

The details

Researchers utilized data from 70 health care organizations to track 11,915 matched pairs of patients over a two-decade period. The study demonstrated that users of adalimumab and infliximab experienced a lower frequency of laser trabeculoplasty and topical ocular hypotensive drop prescriptions.

The study evaluated records spanning from 2006 to 2026.
The findings were published in the American Journal of Ophthalmology on October 22, 2026.

Health Landscape

This study leverages the TriNetX database to conduct a population-level analysis of medication effects. It marks a significant milestone in linking systemic anti-inflammatory therapies to reduced risk of secondary ocular neurodegenerative conditions.

Patients currently taking TNF-α inhibitors should discuss these findings with their ophthalmologist to understand how their medication may influence their long-term eye health. While these results are promising, patients must remain aware that anti-TNF therapy carries a known risk of tuberculosis reactivation.

The takeaway

These findings indicate that systemic inflammation management may have unintended but positive benefits for ocular health. Patients should prioritize regular eye exams regardless of their medication profile to monitor for early signs of glaucoma.